Regen-COV Monoclonal Antibody Infusion at Sacred Heart Emergency Center
Sacred Heart continues to provide the most up-to-date treatment options for COVID-19. Sick COVID patients and people who have been exposed to COVID-19 now have a new monoclonal antibody treatment.
Sacred Heart Emergency Center is playing an important role in reducing the severity, duration, and hospitalization rates for high-risk patients thanks to the recent emergency Use Authorization (EUA) of monoclonal antibody therapy. This medication, which is administered in a single visit, ensures patient safety while also increasing favorable outcomes, offering our most vulnerable patients a higher chance of recovery.
What is a monoclonal therapy?
Monoclonal antibody therapy is effective not only for high-risk patients with COVID-19 symptoms, but also for people who have only been exposed to the virus through close contact. The treatment involves a short outpatient infusion session for patients diagnosed with COVID-19 who have symptoms, and it is approved for persons over the age of 12 who are at high risk of developing severe COVID-19 symptoms or needing hospitalization. The therapy has been shown in studies to reduce hospitalizations. Monoclonal antibody therapy is now being used to treat people who have been exposed to COVID-19 but have not yet tested positive for the virus or developed symptoms (post-exposure prophylaxis, or PEP).
What is the procedure for receiving Regeneron monoclonal antibody therapy or post-exposure injections?
Please call Sacred Heart Emergency Center at (832) 358-0200. We are open 24/7/365. You must qualify to receive the treatment, and all patients must be pre-screened for eligibility prior to visiting our ER. You will not be allowed to receive the treatment if you do not get pre-screened, before visiting our facility.
What does post-exposure prophylaxis (PEP) entail?
This treatment is only for COVID-19 post-exposure prevention in adults and children aged 12 and above who weigh at least 88 pounds. Four injections are given just beneath the skin as part of the PEP treatment. All four injections would be given in one appointment, with a one-hour observation period afterward. PEP is indicated for the following conditions:
- Those at high risk of developing severe COVID-19, including hospitalization or death,
- Those not fully vaccinated or not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, people with immunocompromised conditions, including those taking immunosuppressive medications), and have been exposed to a SARS-CoV-2-infected individual consistent with cl (for example, nursing homes or prisons)
- Those who are at a high risk of being exposed to someone infected with SARS-CoV-2 due to the presence of SARS-CoV-2 infection in other people in the same institution (for example, nursing homes or prisons)
It’s essential to remember that PEP is not a substitute for vaccination. We strongly advise everyone to get vaccinated against COVID-19.
Who is a high-risk patient who might benefit from monoclonal antibody therapy?
High risk includes any of the following characteristics:
- A person who is 65 years old or older
- Overweight (body mass index over 25)
- Chronic kidney disease (a condition that affects the kidneys)
- Type 1 or 2 diabetes
- Immune system is weakened, and you’re on immunosuppressive medication right now.
- Hypertension/cardiovascular disease
- Chronic obstructive pulmonary disease (COPD)
- Sickle cell disease is a type of sickle cell illness.
- Disorders of the nervous system
- Technological dependency in the medical field
Other medical illnesses or circumstances may put a patient at a higher risk of developing severe COVID-19.
Monoclonal antibody therapy should be started as soon as possible following a positive COVID-19 viral test and within 10 days of the onset of symptoms. Patients who have started or finished COVID-19 immunization will be evaluated to see if monoclonal antibody therapy is beneficial.
What if I’m expecting a child or nursing a baby?
There is a scarcity of information on how to treat pregnant women and mothers who are breastfeeding. The benefit of getting infusions or PEP may outweigh the risk of the treatment for a mother and her unborn child. If you’re pregnant or breastfeeding, talk to your doctor about your alternatives and your individual case.
What are the COVID-19 monoclonal antibody therapy’s potential negative effects?
An allergic reaction is one possible side effect of monoclonal antibody therapy. Allergic responses can occur during and after monoclonal antibody treatment infusion. If you have any of the following signs and symptoms of an allergic reaction, contact your doctor right away: fever, chills, nausea, headache, shortness of breath, low blood pressure, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, and dizziness.
Brief pain, bleeding, bruising of the skin, soreness, swelling, and infection at the infusion site are all possible side effects of receiving any medicine by vein. These aren’t all of the COVID-19 monoclonal antibody therapy’s negative effects. Because COVID-19 monoclonal antibody therapy is still being researched, all of the hazards may not be recognized at this time.
As a result of the infusion, I’m feeling considerably better now. Is it possible for me to end my isolation and return to work or resume my normal activities?
No, continue to limit your exposure to other people for at least 24 hours after your symptoms have improved and you haven’t had a fever without using fever-reducing drugs for 10 days after your symptoms first arose. Staying in isolation entails staying at least 6-feet away from others, washing your hands, sanitizing commonly shared hard surfaces, and staying in your own home. After you’ve completed all of the prerequisites for ending your isolation, you can return to work.
After receiving a monoclonal antibody infusion or injections, may I get the COVID-19 vaccine?
Before initiating or continuing a COVID-19 vaccination or vaccine series, patients should wait 90 days after receiving a Regeneron monoclonal antibody treatment. During this time, monoclonal antibody therapy is believed to produce temporary immunity.
Where can I get additional information about the REGEN-COV for COVID-19?
Please visit the Regeneron website for additional information about this treatment.